Connect with us
Rasonque lists at $39,800 a month after FDA approval, yet Medicare’s $2,100 Part D cap can close a patient’s share...
AB 2244 would put a state Non-Ultraprocessed Certified seal on grocery packages, tying supermarket labels to California’s school-food UPF rules before a.
Congo’s Bundibugyo Ebola outbreak has killed 3,007 people, and the only licensed shot now going into arms is still a Zaire vaccine WHO will not endorse...
Medicare's GLP-1 Bridge sells Wegovy and Zepbound for $50, then routes sleep apnea and diabetes patients back to Part D copays of hundreds of dollars.
The 2026 heart attack definition recodes SCAD and spasm as primary attacks and requires sex-specific troponin cutoffs.
Hospital lobbyists want Medicaid cuts rolled back, yet the rural fund caps hospital care pay at 15 percent before 2027 work rules hit.
Rasonque nearly doubled last-line pancreatic survival in RASolute 302, then arrived at $39,800 for 30 days, with a copay path that often skips Medicare.
Elecsys pTau217 is cleared for adults 55 and older, but a positive or intermediate Alzheimer's blood test still needs backup.
AstraZeneca’s Wainua miss lets stabilizer drugs claim first-line ATTR-CM care as Alnylam defends Amvuttra’s trial design.
AstraZeneca’s Wainua missed its ATTR-CM endpoint, and the 1.14 combo ratio cements oral stabilizer pills as first-line care over gene silencers.
Rural patients lose Medicaid coverage and local hospital services under $1.1 trillion in tax-law health cuts a $50 billion rural fund does not offset.
